At this moment the FDA is strongly considering a drug that could effectively treat one of the planet's most prolific diseases...
...A medical problem affecting nearly 20% of the world's population.
But just 7 days from now, one biotech company's announcement could change everything.
It's announcing its pivotal Phase 3 data to the public. And for investors, all eyes are on this data.
Now here's the thing.
Our team of analysts have already profited from this trade -- to the tune of 44% in less than a week.
And now they're all set to pounce on Round 2 of the profits.
Keep reading below to learn what they're up to, and how they're doing it.
It's a drug that could cure one of the planet's most prolific diseases.
A medical problem affecting nearly 20% of the world's population, as well as 30% of the U.S. population, according to the CDC.
The World Health Organization expects its levels to swell 75 percent to 700 million people by 2015... an "epidemic tied to rising diabetes and heart disease rates," from the group's Web site.
This global medical crisis has escalated at such an alarming rate, there's an all-out race to treat it.
And on March 31, the company leading the way in the fight to control this epidemic will share the first of its two-part FDA Phase 3 study results.
To say this announcement is highly anticipated is a gross understatement.
Because if the results are positive, this announcement could result in this tiny biotech company producing the best-selling drug in world history. (The drug has already passed Phase 1 and Phase 2 of its FDA clinical trials.)
And it could make early investors a historic windfall.
Of course the medical problem I'm referring to is obesity.
But I'm here to tell you... It doesn't matter if the results of the March 31 announcement are good, bad, or neutral.
Regardless of the outcome, we stand to profit -- most likely inside the next 7 days. It's the second step in our "double-barreled" trade.
Let me show you what I mean.
The "Double-Barreled" Prize...Round 1: 44% Gains off a Classic "Price Spike"Round 2: The Sky's the Limit
It's simple, really. Only a month ago, this biotech stock's share price shot up -- artificially -- on a rogue wave of hype that was certain to come crashing down. After all, when you see a stock moving -- on ZERO NEWS -- a major red flag is signaled.
Fact is, the stock was insanely overbought. It was "walking the talk."
With all this activity, the share price rose above the upper Bollinger Band -- a technical indicator we use heavily in our research. This pattern we detected above the upper Bollinger Band alerted my team and I to an extremely bearish setup. We knew we were dealing with a decidedly overbought condition... one in which our readers could bank a major profit pop.
You see, the share price had to come down. The profit takers ensured it... like lions circling an easy kill. Traders were taking short positions in massive numbers, betting the share price would take a hard fall after the bogus, over-hyped run-up.
That's why we played a "put" option... to profit as the stock fell back down.
After 7 days we closed the put option. Readers who acted on our trade left with 44% in their pockets.
But now the time has come to play Round 2... the long side of our trade.
That's Because -- on March 31 -- We'll Be Getting the News Everyone's Been Waiting for
That is, the critical Phase 3 data on a drug that can:
Cause weight loss
Is completely safe for the heart, and
Has minimal to no side effects
Its goal: to produce a minimum 5% loss of body weight for patients taking the drug.
Of course, word of this kind of drug being available is about as good as it gets for the roughly two-thirds of U.S. adults considered either overweight or obese. After all, this epidemic, along with its associated conditions and diseases, is responsible for about 9 percent of national health care spending, according to a U.S. Surgeon General's report.
What's more -- not a single drug available on the market today can cure this growing global epidemic.
To catch you up on the drug's latest progress...
Two separate analyses -- conducted by independent safety monitors in a 2006 research study -- report this obesity drug to be safe, after both a six-month interval, and a year of follow-up.
And following the announcement on its Phase 3 data just 7 days from now, the company expects the following to go down, in order:
A peer-reviewed presentation of its data at an undisclosed conference...
A new announcement of its revised data in the fall, and, finally...
Submission of its New Drug Application to the FDA sometime near the end of 2009.
But like I mentioned above, whatever is announced on March 31st won't matter one iota.
That's because of one factor that's practically assured...
You see, the swirling speculation alone on this stock's massive potential should cause its share price to rise, in anticipation of the March 31 announcement.
Another way to look at it...
Get in right now, and ride the announcement's hype to easy short-term profits.
And if the news is even close to what we're expecting, you could be looking at something even better... extreme, long-term profits.
Now while the FDA hasn't approved a true blockbuster drug in quite some time, it's not a stretch to say they're the one government agency that's actually on a roll...
In 2008, the FDA approved 24 first-of-a-kind drugs. That's up from a total of 18 in 2007, 22 in 2006 and 20 in 2005.
Truth is, this really could be the next blockbuster biotech play... bigger than the hottest-selling drugs of the last decade, combined... including Lipitor, Viagra and Zoloft.
And we have our targets set for an...
80% Near-Term Gain
That's right. We expect the announcement on March 31 will be nothing but positive.
The drug, which helps patients "feel full" by honing in on the brain's serotonin receptor, could answer the single biggest question mark the FDA is addressing right now.
That is, the question over damaging side effects.
And an independent safety monitoring board's 12-month review has something to say about that. It found little or no reason to suggest risk to patients... unlike what contributed to the failures of predecessor medications.
Now only two things stand in the way of this biotech drug:
1. The desired safety and efficacy data from its Phase III program.
2. FDA approval.
What's more intriguing, this obesity drug has something else in its favor:
The world needs it.
According to the government's own statistics, the number of Americans considered obese now exceed the number of Americans deemed "just" overweight. Then there's the study just published in the U.K. medical journal The Lancet.
It found that carrying a full one-third more weight than what doctors would consider ideal equates to the same death risk as being a lifetime smoker.
David Katz, founder of Yale University's Prevention Medicine Center in New Haven, CT, had this to say in an interview with Bloomberg... "This is a reaffirmation of how fundamentally important it is for society to rally against" obesity... The takeaway message is that obesity is lethal."
Which is why the market for a fat-busting drug -- without the dangerous side effects -- is worth billions.
And if the results of this obesity drug's 12- to 24-month safety study is as good as what's being indicated, we could be looking at an investor buying spree across the globe.
Still yet, there's...
One More Profitable Possibility
Looking beyond the safety study, the company's drug could be partnered with one of the major biotech companies... and the potential is mind-boggling. Given that the CDC reports 30% of Americans are obese, as compared to 14.6% in 1971, the market is obviously huge.
You see, the potential for annual sales in this market is $10-$15 billion. And with what they bring to the table, this small biotech company could be a serious buyout target.
As I said, it's a company that could literally make a lifetime's fortune for some investors.
Sure, approval of this drug won't happen until the end of 2009 or early 2010... assuming the results are positive.
But the real window for getting in early -- to capture the biggest possibe gains -- is right now... specifically within the next 7 days.
Again, here's how it could go down:
Before March 31, the stock will shoot up on positive results. To be sure, we'll have gotten in well before the herd.
Of course, this profit maneuver isn't for everyone.
It's only for those investors willing to make a fortune in a small cap stock that has investors everywhere salivating.
So if you're one of those investors...
Why Pay Thousands for this Level of Research?Especially Knowing You Can Pay Far Less...
Frankly, it's all part of the Small Cap Trading Pit philosophy...
In short, we dominate the once-inscrutable small-cap sector by being first to the scene.
This is the sector where the real money is made... where every investor dreams of "hitting it big"... and where a stake of just a few thousand dollars could secure your entire retirement.
Ironically, most mainstream financial publications won't touch it with a 10-foot pole. And that just leaves more room for investors like us to tap into an incredible advantage. Put plainly, we detect these soon-to-be leaders of their industries among thousands of bottoms-up companies running on nothing more than rumor and fluff.
The reason for finding one outstanding small cap investment after another can be summed up in one word -- leverage.
And we use this leverage in the sector where index-crushing companies get their start. It's the birthplace of Fortune 500 leaders such as Cisco Systems, Best Buy, and even the #1 Fortune 500 company, Wal-Mart.
In fact, the 2007 Ibbotson yearbook, considered the bible of the investment analysis community, recently announced that since 1925, small caps have outperformed large caps by more than 21% a year!
What's even more eye-opening is that roughly just 1% of the companies in this sector ever make any money. But that handful of stocks launches so high, so fast, that it carries the entire sector's average above already-established large caps.
In fact, because of how the market's responding to the dollar, rising gold prices, and the collapse of the sub-prime sector, we've discovered what could be the most explosive opportunities yet.
All you have to do to begin sharing in the wealth is accept this simple invitation to join my group of investors and me.
Welcome to the Small Cap Trading Pit.
As the name implies, to keep leverage to a maximum, hardly a single opportunity will have a market cap higher than $500 million.
I know that might seem large, but in the investment world, it's really not. Just look at Wal-Mart's massive market cap of over $185 billion -- compared to the $205 million it started out with. The story's the same for scores of other Fortune 500 companies.
So if you're looking for an advisory that requires only a tiny bit of money to uncover the world's future blockbusters and make an absolute fortune, this is it. It's perhaps the fastest, most efficient way an investor can make several hundred -- even thousand -- percent gains.
Every other week, a new issue of SC Trading Pit enters email boxes across the world.
Each issue will explain all the details of our latest SC Trading Pit recommendations. These are the companies that my research team and I thoroughly examine using the same painstaking criteria that's brought me a loyal following -- year in, year out -- across the globe.
On top of that, you'll also receive the latest updates from the companies currently in the SC Trading Pit portfolio. You'll be among the first to know about any company updates, news, progress and deals that are coming down the pike.
And of course, with any stock my team and I recommend or sell (for a profit, of course), you'll know where to buy it, how much you stand to make, and most importantly, when to sell.
We'll also rush every new member a list of the secret criteria we personally use to find these companies. It's the easy-to-understand guide we call The Ten Maxims of Fortune.
That way, not only can you analyze for yourself the companies we recommend and test them to see how they match up... but you can also use this report to find hidden opportunities of your own.
What's more, this report can be adapted to help you determine the attractiveness and probability of success of virtually every stock in the market.
It's yours FREE, as an added bonus just for joining SC Trading Pit.
I encourage you to print it out, keep a copy of it and use it for every opportunity you're considering, now and in the future.
And best of all...
You get all this for less than the cost of the Wall Street Journal.
As the trend goes, the more general a publication, the lower the price.
Take a look at some of the mainstream outlets. They're all extremely vague, big-picture and generalized. They run between $79 and $250 a year.
Don't get me wrong. We're not running them down at all. In fact, there's a copy of the Financial Times on the table as I write this letter. But the truth is, we don't care about a good chunk of what's in there.
It all concerns BIG business... and while it's valuable for reading up on any safe, already-established company, most truly wealthy investors have made the bulk of their money from the exact opposite.
That's why I created SC Trading Pit in the first place.
Now, typically, a highly specific service like SC Trading Pit would cost several thousand dollars a year. But we're not going to go anywhere near what our competitors charge.
The price for an annual membership in SC Trading Pit?
It's Only $99 a year.
That's right. An annual membership in SC Trading Pit is just a hair over $0.27 a day!
For that, you get the following:
Instant access to the Small Cap Trading Pit portfolio,
All the details of our new biotech recommendation, compiled in our new report: The Double-Barreled Biotech Profit Play (which includes step-by-step instructions on executing each of the two trades),
Investment Report #2: The 10 Maxims of Fortune
Plus, 26 information-packed issues detailing the opportunities in the explosive small cap sector, industry updates, and our latest stock recommendations.
My guarantee to you:
If for any reason SC Trading Pit doesn't match up to your expectations, simply let me know within the first 30 days, and I'll refund every penny. No questions asked!
That's about as good as I can make it.
But you'll need to act quickly, in order to profit on the amazing new biotech trade we've brought to your attention here.
No comments:
Post a Comment